Linezolid injection solution for infusion

Maa: Armenia

Kieli: englanti

Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiivinen ainesosa:

linezolid

Saatavilla:

Liqvor CJSC

ATC-koodi:

J01XX08

INN (Kansainvälinen yleisnimi):

linezolid

Annos:

2mg/ml

Lääkemuoto:

solution for infusion

Kpl paketissa:

plastic pack 300ml

Prescription tyyppi:

Prescription

Valtuutuksen tilan:

Registered

Valtuutus päivämäärä:

2021-05-21

Pakkausseloste

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
LINEZOLID INJECTION
SOLUTION FOR INFUSION 600 MG/300 ML
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or
nurse. This includes any possible side
effects, including those not listed in section 4 of this leaflet.
WHAT IS IN THIS LEAFLET
1.
What LINEZOLID injection is and what it is used for.
2.
What you need to know before you are treated with LINEZOLID injection.
3.
How to use LINEZOLID injection.
4.
Possible side effects.
5.
How to store LINEZOLID injection.
6.
Contents of the pack and other information
1.
WHAT LINEZOLID INJECTION IS AND WHAT IT IS USED FOR
LINEZOLID injection is an antibacterial drug of oxazolidinones group.
It stops the growth of certain
bacteria (microbes) that cause infectious diseases. Linezolid is used
for the treatment of nosocomial
and community-acquired pneumonia, complicated skin and skin structure
infections (including
diabetic foot infections, without concomitant osteomyelitis),
vancomycin-resistant
_ _
_Enterococcus _
_faecium _
infections, including cases with concurrent bacteremia.
Your doctor will decide if LINEZOLID injection is suitable for the
treatment of your infectious
disease.
2
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE TREATED WITH LINEZOLID INJECTION
DO NOT TAKE LINEZOLID INJECTION IF:
• you are allergic to linezolid or any of the other ingredients of
this medicine (listed in section 6 of
this leaflet).
•
you are taking or have taken within the last 2 weeks monoamine oxidase
inhibitors (for example,
phenelzine, isocarboxazid). These medicines may be used to treat
depression or Parkinson’s disease.
•
you have uncontrolle

Valmisteyhteenveto

(
)
1.
,
600
/300
2.
2
6.1
:
3.
:
4.
4.1
-
,
,
,
.

_ _
_Staphylococcus _
_aureus_
_Streptococcus Pneumoniae _
,

Streptococcus pneumonia (
_Staphylococcus _
_aureus_
,

_ _
_ Staphylococcus aureus_
_) Streptococcus pyogenes _
_ Streptococcus _
_agalactiae_
,_ _

,
,
_ Enterococcus faecium_
: _ _
4.2.
(
)
:
30-120
:
:
,
:
,
,
100%
:
,
,
:
*
,
(12
)
(
** 11
)
600
12
10
/
8
10-14
,
,
,
_ _
_Enterococcus _
_faecium_
_ _
600
12
10
/
8
14-28
**
.
-
.
_ _
-
_ _
_ _
4.3.

/
6.1
,

A
B
(
,
)
,
2
:

,

,
,
,
,
,
,

(
,
,
),
(
,
),
(
),
,
, 5-
1
(
),
,
:
4.4
,
,
:
:
_ _
_ _
_ _
_ _
,
:
_ _
_ _
_ _
(
2
)
,
,
,
:
:
:
,
.

,

,

/
,

,

2
:
,
:
,
:
:
,
:
,
28
:
:
_ _
_ _
_ _
_ _
,
28
,
(
)
: 28
(
)
:
:
(
,
,
,
)
:
(28
)
,
:
:
:
_ _
_ _
,
(
,
)
:
(
4.3
),
:
(
,
(
),
)
:
:
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
[78/363
(21,5%)]
/
/
[58/363
(16,0%)
:
:
(
0,96;
95%
. 0,58-1,59),
(p=0,0162)
,
(
2,48; 95%
. 1,38-4,46):
`
7
:
:
,
(
4.1
):
:
:
_ _
_ _
_ _
_ _
_ _
_ _
,
:_ _
_Clostridium difficile _
,
:
:
,
_ Clostridium difficile-_
:
A
B
,
:
, _Clostridium _
_difficile _
:
,
:
,
:
:
_Clostridium _
_difficile _
2
:
_ _
:
,
,
-
:
_ _
,
:
:
_ _
_ _
_ _
_ _
_ (_
_)_
:
,
:
/
:
_ _
_ _
_ _
,
,
(
),
,
28
:
_ _
_ _
_ _
_ _
(
,
,
,
)
:
_ _
_ _
_ _
_ _
:
:
_ _
:
:
,
3%-
:
:
28
:
«
»
,
,
:
,
:
_ _
_ _
300
(1
)
51,9
(1194
)
,
:
4.5
_In vitro _
:
D6,
:
,
CYP450-
:
CYP2C9
(S)-
:
CYP2C9
,
,
:
(Cmax)
(AUC)
21 %-
32 %-
:
:
,
,
:
:
,
.
(
,
,
,
,
),
(
):
:
(
)
:
,
(
)
:
4.6.
_ _
:
,
:
_ _
_ _
_ _
:
:
,
:
4.7.
:
,
:
4.8
.
<1/1000),
(<1/10000),
(
):
:
(8,3%),
(5,7%),
(6,6%),
(4,3%):
_ _
_ _
_ _
.

(
,
),
,

(
),
,
*:
_ _
_ _
_ _
_ _
.

*
ǂ
,

*,
,
*,
,

*,

*,
*:
_ _
_ _
.

:
_ _
_ _
_ _
_._

,

*:
_ _
.

:
_ _
_ _
_._

,
(
«
»
),
,

*,
,
,

**,
*:
_ _
_ _
_ _
_._

*,

*,

*,
*,
*,
*,
*:
_ _
_ _
_ _
_ _
_._

:
_-_
_ _
.

,

(
),
,
,
:
_-_
_ _
_._

,
,
,
,
,
,

,
,
,
,
,
,
,
,

:
_-_
_ _
_. _

,
,
,
,
,

:
_ _
_ _
_ _
_ _